ADIPOQ and metabolic dysfunction-associated steatotic liver disease: In a 12-week study in NAFLD patients, every-other-weekly administration of up to 100 mg BFKB8488A, the highest adequately tolerated dose, reduced liver fat by about 40%, serum triglycerides and Pro-C3 by up to 25 to 30% from baseline, while increasing adiponectin by up to 40% and HDL-cholesterol by up to 20% (301).